Despite the presence of many hematological prognostic indexes, clinical course and overall
survival are often highly variable even within the same patient subgroup. Recent studies …

Lymphoma is a common hematologic malignant tumor that originates from lymph nodes or
other lymphoid tissues. The tumor microenvironment (TME) plays an indispensable role in …

For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20–based
immunochemotherapy or develop relapsed or refractory disease, there remains a significant …

Background Obinutuzumab with polatuzumab vedotin or lenalidomide showed tolerability
and activity in phase 1b/2 trials that recruited patients with relapsed or refractory follicular …

EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how
EZH2 affects patients' response to therapy. In this context, the aim of this study was to …

Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a
heterogeneous group of malignancies sharing similar disease courses and treatment …

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-
arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 …

The topic of fertility preservation in patients with a lymphoproliferative disease offers new
aspects of debate, due to the introduction of novel chemotherapeutic regimens and small …

Indolent B-cell non-Hodgkin lymphomas (B-NHL), chronic lymphocytic leukemia (CLL), and
mantle cell lymphoma (MCL) are widely treatable but typically incurable with conventional …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are chimeric antigen
receptor (CAR) T-cell therapies used to treat adult patients with relapsed or refractory …